This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
by Zacks Equity Research
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
by Zacks Equity Research
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
by Zacks Equity Research
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
by Zacks Equity Research
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
by Zacks Equity Research
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
by Zacks Equity Research
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
Q2 Earnings & CPI Data for June: Global Week Ahead
by John Blank
June Consumer Price Inflation (CPI) data lands for the U.S. and U.K., and GDP growth and Retail Sales numbers come out for Mainland China.
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
by Zacks Equity Research
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
by Zacks Equity Research
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
by Zacks Equity Research
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.